Marshall Wace’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-5,155,402
| Closed | -$114M | – | 3087 |
|
|
2024
Q4 | $114M | Buy |
5,155,402
+2,410,420
| +88% | +$43.9M | 0.14% | 126 |
|
|
2024
Q3 | $49.5M | Sell |
2,744,982
-1,427,611
| -34% | -$25M | 0.06% | 283 |
|
|
2024
Q2 | $67.8M | Sell |
4,172,593
-42,623
| -1% | -$657K | 0.09% | 209 |
|
|
2024
Q1 | $59.5M | Buy |
4,215,216
+2,152,814
| +104% | +$27.1M | 0.09% | 218 |
|
|
2023
Q4 | $21.5M | Sell |
2,062,402
-318,572
| -13% | -$2.97M | 0.04% | 464 |
|
|
2023
Q3 | $24.3M | Buy |
2,380,974
+1,182,072
| +99% | +$11M | 0.05% | 376 |
|
|
2023
Q2 | $9.03M | Buy |
+1,198,902
| New | +$9.72M | 0.02% | 782 |
|
|
2023
Q1 | – | Sell |
-48,771
| Closed | -$445K | – | 3098 |
|
|
2022
Q4 | $445K | Buy |
48,771
+1,273
| +3% | +$11.1K | ﹤0.01% | 2420 |
|
|
2022
Q3 | $383K | Sell |
47,498
-2,052,207
| -98% | -$18.1M | ﹤0.01% | 2842 |
|
|
2022
Q2 | $15.8M | Buy |
+2,099,705
| New | +$18.3M | 0.03% | 584 |
|
|
2022
Q1 | – | Sell |
-1,049,916
| Closed | -$8.41M | – | 4008 |
|
|
2021
Q4 | $8.41M | Buy |
1,049,916
+1,030,470
| +5,299% | +$9.3M | 0.02% | 998 |
|
|
2021
Q3 | $190K | Buy |
+19,446
| New | +$182K | ﹤0.01% | 2810 |
|
|
2019
Q3 | – | Sell |
-1,935,491
| Closed | -$17.9M | – | 1923 |
|
|
2019
Q2 | $17.9M | Buy |
+1,935,491
| New | +$23.3M | 0.15% | 153 |
|
|
2018
Q3 | – | Sell |
-25,484
| Closed | -$620K | – | 1280 |
|
|
2018
Q2 | $620K | Buy |
+25,484
| New | +$520K | 0.01% | 557 |
|
|
2016
Q4 | – | Sell |
-231,251
| Closed | -$10.6M | – | 1114 |
|
|
2016
Q3 | $10.6M | Buy |
+231,251
| New | +$12.1M | 0.08% | 271 |
|
|
2016
Q2 | – | Sell |
-210,159
| Closed | -$11.2M | – | 1165 |
|
|
2016
Q1 | $11.2M | Sell |
210,159
-922,492
| -81% | -$54.1M | 0.11% | 198 |
|
|
2015
Q4 | $74.3M | Buy |
1,132,651
+1,080,061
| +2,054% | +$66.7M | 0.7% | 20 |
|
|
2015
Q3 | $2.97M | Sell |
52,590
-79,709
| -60% | -$5.17M | 0.04% | 373 |
|
|
2015
Q2 | $7.82M | Buy |
132,299
+102,182
| +339% | +$6.3M | 0.1% | 222 |
|
|
2015
Q1 | $1.88M | Sell |
30,117
-68,463
| -69% | -$3.98M | 0.02% | 477 |
|
|
2014
Q4 | $5.67M | Sell |
98,580
-282,318
| -74% | -$15.7M | 0.07% | 284 |
|
|
2014
Q3 | $20.5M | Sell |
380,898
-59,516
| -14% | -$3.15M | 0.3% | 99 |
|
|
2014
Q2 | $23.1M | Buy |
440,414
+73,343
| +20% | +$3.75M | 0.34% | 80 |
|
|
2014
Q1 | $19.4M | Buy |
+367,071
| New | +$17M | 0.35% | 84 |
|
Other funds holding TEVA
HIIFS
PF
MMH
CI
MIFH
LIM
Marshall Wace's TEVA Position: Q1 2025 in Review
Marshall Wace sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 5,155,402 shares — an estimated $114M sold.
Marshall Wace first reported a position in TEVA in Q1 2014 and held it in 24 quarters. The position peaked at $114M in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.
- Marshall Wace reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Marshall Wace sold 5,155,402 Teva Pharmaceuticals shares in Q1 2025, an estimated $114M.
- Marshall Wace first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 24 quarters.
- Marshall Wace's Teva Pharmaceuticals position peaked at $114M in Q4 2024.
- 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.
Based on Marshall Wace's 13F filing for Q1 2025, filed 15 May 2025.